AstraZeneca's (AZN) sBLA for Enhertu Gets FDA's Priority Tag
AstraZeneca's (AZN) sBLA for Enhertu to treat metastatic HER2-positive solid tumors gets priority review status by the FDA. A final decision is expected in second-quarter 2024.
GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?
We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal
Data from a late-stage shows that AstraZeneca's (AZN) cancer combination therapy reduces the risk of disease progression or death in certain liver cancer patients by 23%.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK and AstraZeneca: A leading investment bank gives its verdict with an upgrade and a downgrade
UBS has revised its stance on two major UK-listed pharma companies - GSK PLC (LSE:GSK, NYSE:GSK) and AstraZeneca PLC (LSE:AZN) - with an upgrade for the former and a downgrade for the latter. GSK i...
AstraZeneca, LSE and Heathrow among 320 co's to make nature-based disclosures in financial results
Over 300 companies, including AstraZeneca, Anglo American, Endeavour Mining, Heathrow Airport and British American Tobacco, will start to include nature-related disclosures as part of their annual ...
Sell AstraZeneca, says UBS, which upgrades European rivals including GSK
UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.
AstraZeneca: Leading bank bullish after key conference appearance
JP Morgan has maintained its bullish stance on AstraZeneca PLC (LSE:AZN) in the wake of the San Francisco healthcare conference it sponsors. Repeating its overweight stance £130 a share price targe...
Astrazeneca (AZN) Laps the Stock Market: Here's Why
In the latest trading session, Astrazeneca (AZN) closed at $69.42, marking a +0.35% move from the previous day.
White House says officials met with Sanofi, AstraZeneca on RSV immunization
Senior U.S. officials met this week with the manufacturers of RSV immunizations for infants, pushing companies including Sanofi and AstraZeneca to continue efforts to meet demand, the White House s...
Here's Why Astrazeneca (AZN) Fell More Than Broader Market
Astrazeneca (AZN) closed at $69.18 in the latest trading session, marking a -0.56% move from the prior day.
AstraZeneca: Rebound in 2024 with double-digit earnings growth
U.K.-based AstraZeneca PLC NASDAQ: AZN is up 8.95% in the past month as investors grow optimistic about the company's improved earnings outlook for 2024. Not only are sales of cancer and diabetes d...
Are defensive sectors ready to outshine growth in 2024?
The Health Care Select Sector SPDR Fund NYSEARCA: XLV, which has both growth and defensive characteristics, was the leader in the first week of the year. Top sector performers included Moderna Inc....
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw Astrazeneca (AZN) settling at $68.38, representing a -0.58% change from its previous close.
Why the Market Dipped But Astrazeneca (AZN) Gained Today
Astrazeneca (AZN) reachead $68.78 at the closing of the latest trading day, reflecting a +0.67% change compared to its last close.
Related Companies